Mirati Therapeutics (MRTX) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

License and Collaboration RevenueProduct Revenue
02M5M8M10M12M15M18M20MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
05M10M15M20M25M30M35M40MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Operating Expenses

Research And Development ExpensesSelling General And Administrative Expenses
038M75M112M150M188M225M262M300MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

EBITDA

EBITDA
-300M-262M-225M-187M-150M-112M-75M-37M1Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

EPS

Revenue Variation (%)

Revenue Variation
-10012125238350462575688800Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
0255075100125150175200Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Revenue YoY Variation (%)

P/E Ratio
-7-6-5-4-3-2-101Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Income YoY Variation (%)

Price-to-Earning Ratio

Cash At End Of Period
050M100M150M200M250M300M350M400MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Income Breakdown

Total AssetsTotal Liabilities
0250M500M750M1B1B2B2B2BQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Per Share Metrics

Total Current AssetsTotal Non Current Assets
0250M500M750M1B1B2B2B2BQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Expense Ratios

Total Current LiabilitiesTotal Non Current Liabilities
038M75M112M150M188M225M262M300MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023
💰 Cash Flow Statement

Operating Cash Flow

Total Stockholders Equity
0250M500M750M1B1B2B2B2BQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Free Cash Flow

Debt To Equity
000001111Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Cash Flow to Debt Ratio

Market Cap
0625M1B2B2B3B4B4B5BQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023
🏦 Balance Sheet
📈 Key Metrics